Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... Able to adhere to the study visit schedule and other protocol requirements. Previously untreated, histologically confirmed ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  2. Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

    ... by cardiology or pulmonary prior to enrollment on this protocol Serum creatinine =<1.5 mg/dL or creatinine clearance > 50 ... some patients with minor deviations may be accepted on protocol after discussion with the principal investigator (PI) Serum ...

    Clinical Trial last updated 05/23/2016 - 2:06pm.

  3. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... Currently enrolled in another investigational therapy protocol Participants with presence of other active malignancy within ... research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  4. Transplants With Unlicensed Preserved Cord Blood

    ... if the transplant will occur under an IND research protocol . These units are in current and future inventory at domestic and ... Indications. This study is an access and distribution protocol conducted by the National Marrow Donor Program (NMDP) for unlicensed ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.

  5. Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

    ... allogeneic peripheral blood stem cell (PBSC) transplant protocol (03-H-0170) for patients with severe sickle cell disease (SCD) and ... (and reduce the transplant failure rate) in this new protocol, we will continue our nonmyeloablative approach in the patients with ...

    Clinical Trial last updated 04/28/2016 - 9:09am.

  6. Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    ... in patients up to the time they begin therapy under this protocol Patients < 12 yrs of age must be discussed on a case by case basis with the primary investigator (PI) of the protocol prior to registration A signed informed consent form or minor ...

    Clinical Trial last updated 04/28/2016 - 2:45pm.

  7. SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

    ... is able to adhere to the study visit schedule and other protocol requirements, including follow-up for response assessments The ...

    Clinical Trial last updated 06/06/2016 - 2:11pm.

  8. Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

    ... considers that HCT on the high-intensity arms of protocol is contraindicated for that patient the patient may be considered for treatment on the lower intensity arm of the protocol or excluded from the protocol; patients with Gilbert's syndrome and no ...

    Clinical Trial last updated 06/06/2016 - 2:55pm.

  9. T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

    ... The primary aim of this protocol is to evaluate if the one-year survival is significantly improved ...

    Clinical Trial last updated 05/03/2016 - 11:43am.

  10. Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic

    ... Able and willing to comply with the requirements of the protocol . Able to understand and willing to sign an IRB-approved ... by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as ...

    Clinical Trial last updated 04/29/2016 - 4:33pm.